

*Unless otherwise defined herein, terms used in this announcement shall have the same meanings as those defined in the prospectus dated May 31, 2017 (the “**Prospectus**”) issued by WuXi Biologics (Cayman) Inc. (the “**Company**”).*

This announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for Shares or any securities. Potential investors should read the Prospectus for detailed information about the Global Offering illustrated below before deciding whether or not to invest in the Offer Shares.

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or any state securities laws of the United States and may be offered and sold (a) in the United States only to persons who are both “*Qualified Institutional Buyers*” and “*Qualified Purchasers*” in reliance on Rule 144A or another exemption from, or in a transaction not subject to, registration under the U.S. Securities Act and (b) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act. The Company has not intended and does not intend to make any public offer of securities in the United States. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and management, as well as financial statements. No registration has been or will be made under the United States Investment Company Act of 1940.*

WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

UPDATE ANNOUNCEMENT

Reference is made to announcement and prospectus of WuXi Biologics (Cayman) Inc. (the “**Company**”) both dated May 31, 2017 respectively (the “**Announcement**” and the “**Prospectus**”) and the announcement of offer price and allotment results of the Company dated June 12, 2017 (the “**Results Announcement**”). This update announcement is supplemental to the Announcement, the Prospectus and the Results Announcement and should be read in conjunction with the Announcement, the Prospectus and the Results Announcement. Unless otherwise stated, terms used in this announcement shall have the same meanings as defined in the Prospectus.

The board of directors of the Company (the “**Board**”) wishes to draw the attention of the applicants who have applied for the Hong Kong Offer Shares through the HK eIPO White Form service whose applications were wholly or partially unsuccessful. Due to the delay encountered by the receiving bank of the Company in remitting the refund monies to the bank retained by the Hong Kong Share Registrar responsible for handling the HK eIPO White Form refund, the refund monies will be despatched to their application payment bank accounts in the form of e-Auto Refund payment instructions on June 13, 2017 instead of June 12, 2017.

By order of the Board of Directors of the Company

Dr. Ge Li

Chairman

Hong Kong, June 12, 2017

As of the date of this announcement, the Board of Directors comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Edward Hu, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Wo Felix Fong as independent non-executive Directors.

** For identification purpose only*